Back Hepatitis C

Hepatitis C

EASL 2014: WHO Recommends Global Use of Newest Hepatitis C Drugs, Urges Price Reductions

The World Health Organization has issued global treatment guidelines for hepatitis C, strongly recommending the use of the new direct-acting antivirals sofosbuvir (Sovaldi) with ribavirin for HCV genotypes 1, 2, 3, and 4, or simeprevir (Olysio) with pegylated interferon interferon and ribavirin for genotype 1 infection. The WHO guidelines were released to coincide with the 49th International Liver Congress this week in London. New guidelines from the European Association for the Study of the Liver (EASL) will be released on Saturday.

alt

Bristol-Myers Squibb Requests FDA Approval of Daclatasvir and Asunaprevir

Bristol-Myers Squibb has submitted New Drug Applications asking the U.S. Food and Drug Administration (FDA) to approve its experimental hepatitis C virus (HCV) NS5A inhibitor daclatasvir and HCV protease inhibitor asunaprevir, the company announced this week.

alt

CROI 2014: Interferon-free BMS Combo Cures 90% of Genotype 1 Hepatitis C

An all-oral regimen of daclatasvir, asunaprevir, and BMS-791325 -- without interferon or ribavirin -- led to sustained response in approximately 90% of previously untreated hepatitis C patients, most with hard-to-treat genotype 1a, according to a study presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this month in Boston.

alt

FDA Grants Priority Review for Gilead's Sofosbuvir + Ledipasvir Coformulation

The U.S. Food and Drug Administration (FDA) has agreed to expedited review of Gilead Science's sofosbuvir plus ledipasvir coformulation for treatment of chronic hepatitis C, putting the combination pill on track for an approval decision by mid-October, the company recently announced.

alt

CROI 2014/APASL 2014: Merck Combo Suppresses HCV in Monoinfected and Coinfected Patients

An all-oral combination of the HCV protease inhibitor MK-5172 and the NS5A inhibitor MK-8742, with or without ribavirin, demonstrated promising end-of-treatment viral suppression in HIV/HCV coinfected patients and high cure rates in people with hepatitis C alone, according to findings from the C-WORTHY study presented at recent conferences.

alt

APASL: Simeprevir Matches Telaprevir in Phase 3 Study, Gets Positive European Regulatory Opinion

The new hepatitis C virus (HCV) protease inhibitor simeprevir has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), recommending marketing authorization in the European Union, Janssen R&D announced this week. The recommendation was based on findings from a set of Phase 3 trials, some of which were presented at the Asian Pacific Association for the Study of the Liver (APASL) conference this month in Brisbane.

alt

APASL 2014: Latest Hepatitis C Treatments Offer Good News for HIV/HCV Coinfected People

People coinfected with HIV and hepatitis C are at risk of faster liver disease progression, so they stand to benefit even more from new direct-acting antiviral therapies that could cure hepatitis C as effectively and be equally well-tolerated in HIV/HCV coinfected and HCV monoinfected patients, Gregory Dore said at the 23rd Conference of the Asian Pacific Association for the Study of the Liver (APASL 2014) last week in Brisbane.

alt

Advances in Hepatitis C Treatment: the Future Is Now [VIDEO]

As effective direct-acting antiviral drugs to treat hepatitis C come into widespread use and interferon-free therapy becomes a reality, patients, providers, and payers are now grappling with issues such as who should receive treatment and how to pay for the new medications.

alt

Hepatitis C Liver Decompensation Remains a Problem for People with HIV Despite Good ART

People with HIV who are coinfected with hepatitis C virus (HCV) continue to have a higher risk for decompensated cirrhosis, or liver failure, even in the era of effective antiretroviral therapy (ART), according to a study published in the March 18 Annals of Internal Medicine. As such, they especially stand to benefit from new interferon-free hepatitis C treatments.

alt